论文部分内容阅读
目的探讨促性腺激素释放激素受体(GnRH-R)在乳腺癌组织中的表达及其与患者临床病理特征的相关性。方法收集了2008年1月至2010年12月江南大学附属医院保存的104例浸润性乳腺导管癌患者的手术切除标本进行回顾性分析。应用免疫组织化学SP法观察乳腺癌组织中GnRH-R的表达,研究GnRH-R与乳腺癌患者临床病理特征之间的关系,并采用χ~2检验进行统计分析。结果乳腺癌组织中GnRH-R的阳性表达率为66.3%(69/104)。GnRH-R的阳性表达率在luminal A型、luminal B型、HER-2过表达型、三阴性乳腺癌患者中分别为5/11、61.4%(27/44)、8/16、87.9%(29/33),差异有统计学意义(χ~2=11.407,P<0.050)。两两比较显示,GnRH-R在三阴性乳腺癌的阳性表达率高于luminal A型(χ~2=8.455,P<0.008)和HER-2过表达型(χ~2=8.361,P<0.008)。乳腺癌组织中GnRH-R的阳性表达率在不同年龄、组织学分级、淋巴结转移状态及临床分期的患者中,差异没有统计学意义(χ~2=0.506,P=0.477;χ~2=0.007,P=0.936;χ~2=2.158,P=0.340;χ~2=0.007,P=0.936)。结论 GnRH-R在三阴性乳腺癌组织中呈高表达,可能为三阴性乳腺癌患者的治疗提供参考。
Objective To investigate the expression of gonadotropin-releasing hormone receptor (GnRH-R) in breast cancer and its relationship with clinicopathological features. Methods A retrospective analysis was performed on 104 patients with invasive ductal carcinoma of the breast preserved in the Affiliated Hospital of Jiangnan University from January 2008 to December 2010. The expression of GnRH-R in breast cancer tissues was observed by immunohistochemical SP method. The relationship between GnRH-R and the clinicopathological features of breast cancer patients was studied. Statistical analysis was performed by Chi-square test. Results The positive rate of GnRH-R in breast cancer was 66.3% (69/104). The positive expression rate of GnRH-R was 5/11, 61.4% (27/44), 8 / 16,87.9% (3/4) in luminal A type, luminal B type, HER-2 overexpression type and triple negative breast cancer patients 29/33), the difference was statistically significant (χ ~ 2 = 11.407, P <0.050). The positive rates of GnRH-R in triple negative breast cancer were higher than those of luminal A (χ ~ 2 = 8.455, P <0.008) and HER-2 overexpression ). The positive expression rates of GnRH-R in breast cancer tissues were not statistically different between patients with different ages, histological grade, lymph node metastasis status and clinical stage (χ ~ 2 = 0.506, P = 0.477; χ ~ 2 = 0.007 , P = 0.936; χ ~ 2 = 2.158, P = 0.340; χ ~ 2 = 0.007, P = 0.936). Conclusion GnRH-R is highly expressed in triple-negative breast cancer tissues, which may provide a reference for the treatment of triple-negative breast cancer patients.